Ortega-Torres SE

Language: Spanish
References: 10
Page: 21-24
PDF size: 93.20 Kb.

ABSTRACT

Objective. To evaluate the time of recovery of the muscular function in patient with sharp outlying facial paralysis with microdoses of laser ray of arsenide of Galio.
Material and methods. It was a prospective, longitudinal, comparative, experimental study carried out of March 2006 to October 2007; 69 patients with diagnosis of sharp outlying facial paralysis were assigned at the experimental group and 69 to the control group, later on both groups were valued by means of muscular manual exam.
Results. The average age was of 40 years (OF 13.4) for the experimental group and 36 years (OF 13) for the control group, the evolution average in days to the moment of its entrance was of 17 days (OF 1.9) for the experimental group and 18 days (OF 1.4) for the control group, the proportion of women is bigger than that of man in both groups (52%); the affected side was the left one for the experimental group (50.7%) and the right for the group control (52%) without significant difference statistically for both; in the experimental group 42 patients (60.8%) supracordal lesion and in 27 patients (39.1%) infracordal and in the control group 31 patients (45%) lesion supracordal and 38 patients presented (55%) infracordal, the lesion supracordal presents a complete functional recovery of 73.8% in the experimental group and 40% in the control group.
Conclusions. The handling and the patients’ evolution in both groups are the same; however, clinically a discreet improvement was observed in the group of patient’s treated with microdoses of laser ray.

REFERENCES

1. Santos-Lasaosa S, López del Val J, Iñiguez C, Ortells M, Escalza I, Navas I. Parálisis facial periférica: etiología, diagnóstico y tratamiento. Rev Neurol 2000; 31: 14-6.

2. Peitersen E. The natural history of Bell’s palsy. Acta Otolaryngol Suppl 2001; 492: 122-4.

3. Ronthal M. Bell’s palsy. Disponible en: http://www.uptodate.com

4. Flores FP, Medina ZR, Haro GL. Tratamiento de la parálisis facial periférica idiomática: terapia física versus prednisona. Rev Med IMSS 1988; 36(3): 217-21.

5. Aboytes CA, Torres VA. Perfil clínico y epidemiológico de la parálisis facial en el Centro de Rehabilitación y Educación especial de Durango, México. Revista Médica del Hospital General de México 2006; 69(2): 70-7.

6. Riordan M. Parálisis facial: evolución y tratamiento. Birmingham Childrens Hospital, Steelhause Lane, Reino Unido. Arch Dis Child 2001; 84: 286-7.

7. Adour KK, Bell DN, Hilsinger RL Jr. Herpes simplex virus in idiopathic facial paralysis. JAMA 2005; 233(6): 527-30.

8. Domínguez-Carrillo LG. Zonas anatómicas de lesión en parálisis facial periférica y su relación etiológica. Experiencia de 780 casos. Cir Cir 2002; 70: 239-45.

9. Rowlands S, Hooper R, Hughes R, Burney P. The epidemiology and treatment of Bell’s palsy in the UK. Eur J Neurol 2002; 9(1): 63-7. 11. Oshiro T, et al. An introduction to Role of Low Reactive-Level Laser Therapy (LLLT). In: Oshiro T, Calderhead RG (eds.). Progress in Laser Therapy Selected Papers from the first meeting of the International Laser Therapy Association. Okinawa; 1990, p. 36-47.

10. Montes CM, Guzmán JM. Evolución y pronóstico de la parálisis de Bell basados en hallazgos clínicos y electromiográficos. México: Tesis UNAM; 1985.